- Home
- BUJA vs BCAB Comparison
BUJA vs BCAB Comparison
Compare BUJA & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- BCAB
- Stock Information
- Founded
- BUJA 2022
- BCAB 2007
- Country
- BUJA Malaysia
- BCAB United States
- Employees
- BUJA N/A
- BCAB N/A
- Industry
- BUJA Blank Checks
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- BUJA Finance
- BCAB Health Care
- Exchange
- BUJA Nasdaq
- BCAB Nasdaq
- Market Cap
- BUJA N/A
- BCAB 96.2M
- IPO Year
- BUJA 2023
- BCAB 2020
- Fundamental
- Price
- BUJA $10.96
- BCAB $2.08
- Analyst Decision
- BUJA
- BCAB Strong Buy
- Analyst Count
- BUJA 0
- BCAB 2
- Target Price
- BUJA N/A
- BCAB $6.00
- AVG Volume (30 Days)
- BUJA 2.7K
- BCAB 1.6M
- Earning Date
- BUJA 01-01-0001
- BCAB 11-08-2024
- Dividend Yield
- BUJA N/A
- BCAB N/A
- EPS Growth
- BUJA N/A
- BCAB N/A
- EPS
- BUJA 0.29
- BCAB N/A
- Revenue
- BUJA N/A
- BCAB N/A
- Revenue This Year
- BUJA N/A
- BCAB N/A
- Revenue Next Year
- BUJA N/A
- BCAB N/A
- P/E Ratio
- BUJA $37.13
- BCAB N/A
- Revenue Growth
- BUJA N/A
- BCAB N/A
- 52 Week Low
- BUJA $10.30
- BCAB $1.14
- 52 Week High
- BUJA $12.18
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- BUJA 67.66
- BCAB 55.80
- Support Level
- BUJA $10.85
- BCAB $1.87
- Resistance Level
- BUJA $10.85
- BCAB $2.13
- Average True Range (ATR)
- BUJA 0.00
- BCAB 0.12
- MACD
- BUJA -0.00
- BCAB 0.00
- Stochastic Oscillator
- BUJA 87.50
- BCAB 68.90
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.